Computational fishing of new DNA methyltransferase inhibitors from natural products

DNA methyltransferase inhibitors (DNMTis) have become an alternative for cancer therapies. However, only two DNMTis have been approved as anticancer drugs, although with some restrictions. Natural products (NPs) are a promising source of drugs. In order to find NPs with novel chemotypes as DNMTis, 4...

Full description

Autores:
Tipo de recurso:
Fecha de publicación:
2015
Institución:
Ministerio de Ciencia, Tecnología e Innovación
Repositorio:
Repositorio Minciencias
Idioma:
eng
OAI Identifier:
oai:repositorio.minciencias.gov.co:20.500.14143/34166
Acceso en línea:
http://repositorio.colciencias.gov.co/handle/11146/34166
Palabra clave:
Biología vegetal
Aceites vegetales
Productos químicos
Anticancer
Screening
QSAR
Docking
Cluster
Biotecnología
Tecnología química
Química agrícola
Rights
License
http://purl.org/coar/access_right/c_f1cf
Description
Summary:DNA methyltransferase inhibitors (DNMTis) have become an alternative for cancer therapies. However, only two DNMTis have been approved as anticancer drugs, although with some restrictions. Natural products (NPs) are a promising source of drugs. In order to find NPs with novel chemotypes as DNMTis, 47 compounds with known activity against these enzymes were used to build a LDA-based QSAR model for active/inactive molecules (93% accuracy) based on molecular descriptors. This classifier was employed to identify potential DNMTis on 800 NPs from NatProd Collection. 447 selected compounds were docked on two human DNA methyltransferase (DNMT) structures (PDB codes: 3SWR and 2QRV) using AutoDock Vina and Surflex-Dock, prioritizing according to their score values, contact patterns at 4 ˚A and molecular diversity. Six consensus NPs were identified as virtual hits against DNMTs, including 9,10-dihydro- 12-hydroxygambogic, phloridzin, 2’,4’-dihydroxychalcone 4’-glucoside, daunorubicin, pyrromycin and centaurein. This method is an innovative computational strategy for identifying DNMTis, useful in the identification of potent and selective anticancer drugs.